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Purpose
Interstitial lung disease (ILD) is a serious adverse effect of gefitinib. We examined the inci-
dence and clinical characteristics of drug-induced ILD in Korean non-small cell lung carci-
noma patients treated with gefitinib.
Materials and Methods
A retrospective cohort study was performed in non-small cell lung cancer (NSCLC) patients
who started gefitinib treatment at Seoul National University Hospital from January 2002
through December 2011. Patients who developed new abnormal radiologic findings with
respiratory symptoms after gefitinib treatment were defined as having possible adverse 
pulmonary reactions. The patients’ medical records were reviewed independently by inves-
tigators to identify the causes of pulmonary toxicities.
Results
Among the 1,114 patients evaluated, 128 patients (11.5%) developed pulmonary adverse
reactions after taking gefitinib. An infectious complication occurred in 98 patients (8.8%)
and 15 patients (1.3%) developed ILD. Nine of the 15 patients (60.0%) with gefitinib-induced
ILD experienced a fatal clinical course that met either the Common Terminology Criteria for
Adverse Events grade 4 (n=3) or grade 5 (n=6). In the multivariate analysis, a lower serum
albumin level (! 3.0 g/dL) at baseline was significantly associated with the development of
gefitinib-induced ILD (odds ratio, 3.91; 95% confidence interval, 1.20 to 12.71). 
Conclusion
The incidence of gefitinib-induced ILD in Korean NSCLC patients was similar to that reported
worldwide, but lower than values reported for Japanese population. ILD was usually a life-
threatening adverse effect of gefitinib, and the development of ILD was significantly asso-
ciated with a lower baseline serum albumin level.
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Introduction
Epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors are well-established treatments for advanced non-
small cell lung cancer (NSCLC) in many countries. They are
generally well tolerated and not associated with the side 
effects typical of cytotoxic chemotherapy. 
Gefitinib (Iressa, AstraZeneca, London, UK) is an orally
administered, reversible tyrosine kinase inhibitor of EGFR.
In 2002, it was approved for the treatment of inoperable or
recurrent NSCLC based on the results of two large-scale mul-
ticenter phase II studies that yielded favorable responses and
low toxicities [1]. The Iressa Pan-Asia Study (IPASS) found
that gefitinib produced longer progression-free survival
compared to carboplatin plus paclitaxel in patients with 
advanced pulmonary adenocarcinoma harboring EGFR
mutations [2]. A more recent phase III trial, conducted in
metastatic NSCLC patients with mutated EGFR, confirmed
these findings [3]. 
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Common adverse events associated with gefitinib treat-
ment are diarrhea, skin rashes, and nausea, but most of these
are mild in severity and manageable [2,3]. However, since
the first report of gefitinib-induced interstitial lung disease
(ILD) from Japan [4], ILD associated with molecularly tar-
geted agents has drawn considerable attention. The inci-
dence of ILD during gefitinib treatment was not infrequent
and varied among ethnicities. The incidence of gefitinib-
induced ILD was approximately 1% in worldwide popula-
tions [1], while the frequency of ILD in the Japanese series
was reported to be much higher than that in the rest of the
world [5]. The incidence in other Asian populations, besides
Japanese, remains uncertain. In Korean patients, several
small prospective studies reported a high incidence (1.3%-
3.7%) of ILD during gefitinib treatment [6-8]. 
Gefitinib-induced ILD is often life-threatening; its mortal-
ity is approximately 30%-40% [9]. However, investigation of
predictive and prognostic factors for gefitinib-induced ILD
is limited. Even less is known about the mechanisms of 
developing ILD. 
In this study, we estimate the incidence of gefitinib-
induced ILD in a large Korean population and describe the
major clinical findings. Furthermore, we evaluate possible
risk and prognostic factors for gefitinib-induced ILD.
Materials and Methods
1. Study populations
A retrospective cohort study was performed with histol-
ogy proven NSCLC patients who were treated with gefitinib
at Seoul National University Hospital from January 2002
through December 2011 [10]. Patient clinical data, including
medical records, radiographic findings and laboratory 
results were reviewed. This study protocol was approved by
the Institutional Review Board (IRB) of the Seoul National
University Hospital (IRB protocol number: H 1308-047-511). 
2. Clinical data collection
The following demographic data were abstracted: age, sex,
comorbidities, smoking history, Eastern Cooperative Oncol-
ogy Group (ECOG) performance status, histologic type, 
previous anticancer treatment and concurrent pulmonary
disease (e.g., pulmonary emphysema or interstitial pneu-
monitis). Adverse events from gefitinib treatment were eval-
uated using the Common Terminology Criteria for Adverse
Events (CTCAE) from the National Cancer Institute ver. 4.0
and a fatal adverse event was defined as being CTCAE grade
4 or grade 5. Treatment response to gefitinib was assessed
according to the criteria of the Response Evaluation Criteria
in Solid Tumors (RECIST) ver. 1.1. We classified a patient
who had partial or complete response as a responder. Labo-
ratory results, including complete blood cell and differential
counts, chemistry tests, and oxyhemoglobin saturation meas-
ured by pulse oximetry (SpO2) performed when gefitinib
treatment began and when ILD occurred were collected.
Overall survival was calculated from the initiation of gefi-
tinib treatment to the date of death or last follow-up. 
3. Confirmation of adverse pulmonary reaction and gefi-
tinib-induced ILD
New abnormal radiologic findings with respiratory symp-
toms after gefitinib treatment were defined as possible 
adverse pulmonary reactions. To identify the cause of an 
adverse pulmonary reaction, two of the investigators (S.-H.B
and S.H.S) reviewed the data independently. If their opinions
differed regarding the cause of an adverse pulmonary reac-
tion, another investigator (D.-W.K.) made the decision. Pul-
monary infiltrates identified as lung cancer progression were
excluded from this evaluation. Adverse pulmonary reactions
were classified as non-infectious and infectious complica-
tions; the causes of non-infectious complications were cate-
gorized using published classifications [11,12]. The diagnosis
of gefitinib-induced ILD was based on published, generally
accepted clinical criteria [9,13]. In brief, for the diagnosis of
ILD, four specific findings were required: (1) progressive
dyspnea with or without cough or fever, (2) lack of evidence
of infection, (3) radiologic findings consistent with drug-
induced ILD (i.e., bilateral, diffuse, or patchy interstitial
and/or alveolar opacifications without evidence of marked
progression of underlying lung cancer), and (4) consistent
pathologic findings, if available. 
4. Statistical analysis 
Categorical clinical variables were compared using a chi-
squared test or Fisher exact test. Continuous variables were
compared using an independent unpaired t test or the Mann-
Whitney U test if the variables were not normally distrib-
uted. Univariate analysis was performed to evaluate
associations between the outcomes of gefitinib-induced ILD
and patient characteristics. Predictive factors for gefitinib-
induced ILD were assessed by multivariate logistic regres-
sion models. Variables with a p-value in the univariate analy-
sis of less than 0.2 were selected for the multivariate analysis.
Overall survival was assessed by Kaplan-Meier method after
onset of ILD in different patient groups. Two-sided null 
hypotheses of no difference were rejected if p-values were
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less than 0.05, or, equivalently, if the 95% confidence inter-
vals (CIs) of risk point estimates excluded 1. All statistical
analyses were performed with SPSS ver. 21.0 (IBM SPSS Sta-
tistics, IBM Co., Armonk, NY).
Results
1. Incidence of adverse pulmonary reaction and gefitinib-
induced ILD
The medical records of the 1,114 patients who received
gefitinib from January 2002 through December 2011 were 
reviewed and abstracted (Fig. 1). Among these patients, 128
patients (11.5%) developed symptomatic pulmonary infil-
trates after treatment initiation. All patients were treated
with gefitinib monotherapy. An infectious pulmonary com-
plication occurred in 98 patients (8.8%), and 30 patients
(2.7%) experienced a non-infectious pulmonary complica-
tion. Fifteen patients (1.3%) with gefitinib-induced ILD were
identified. 
2. Risk factors for gefitinib-induced ILD
In multivariate analysis, only a lower serum albumin level
was significantly associated with the development of gefi-
tinib-induced ILD after adjusting for sex, hypertension and
coincidence of ILD (odds ratio, 3.91; 95% CI, 1.20 to 12.71)
(Tables 1 and 2). The association between the coincidence of
ILD before treatment and the development of gefitinib-
induced ILD was not significant statistically. The model fit
was confirmed with the Hosmer-Lemeshow goodness of fit-
ness test (p=0.419). 
3. Clinical characteristics of gefitinib-induced ILD
Clinical and laboratory findings of gefitinib-induced ILD
are summarized in Table 3. The median time interval from
the start of gefitinib administration to onset of ILD was 29.0
days (range, 3 to 1,953 days) (Fig. 2). In 12 patients (80.0%),
ILD occurred during the first 8 weeks of gefitinib treatment.
Gefitinib was used as second or later line treatment. In three
patients (20.0%), the computed tomography (CT) findings at
the time of ILD diagnosis revealed combined lung cancer
progression. ILD developed in one patient (6.7%) who 
responded to gefitinib treatment. The most common clinical
presentation of gefitinib-induced ILD was dyspnea (100%),
followed by cough (60.0%). Two patients (13.3%) presented
with fever at the onset of ILD. Severe hypoxemia was found
and the mean SpO2 was 80.47% on room air. Leukocytosis
and elevated level of C-reactive protein (CRP) were common;
mean leukocytes count was 13.90!103/µL and mean CRP
level was 12.01 mg/dL. No patient presented with eosino-
philia at the time of ILD diagnosis. The mean albumin level
Gefitinib treated patients at SNUH
(n=1,114)
Developed adverse pulmonary reaction
(n=128, 11.5%)
Non-infectious complications
(n=30, 2.7%)
Gefitinib-induced
interstitial lung
disease
(n=15, 1.3%)
Radiation
pneumonitis
(n=4, < 0.1%)
Cases of
infectious cause
(n=98, 8.8%)
Did not develop adverse
pulmonary reaction
(n=986, 88.5%)
Non-cardiogenic
pulmonary
edema
(n=1, < 0.1%)
Unknown
cause
(n=10, 0.1%)
Fig. 1. Outline of patient recruitment and distribution of adverse pulmonary reactions. SNUH, Seoul National University Hospital.
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Table 1. Univariate analysis of risk factors for gefitinib-induced interstitial lung disease (ILD)
Variable Total (n=1,114) Gefitinib-induced ILD
No (n=1,099) Yes (n=15) OR (95% CI) p-value
Mean age (yr) 60.34 (25-91) 60.34±11.42 60.69±12.01 1.00 (0.96-1.05) 0.906 
Sex 
Male 514 (46.1) 510 (46.4) 4 (26.7) 1 ( 0.139a)
Female 600 (53.9) 589 (53.6) 11 (73.3) 2.38 (0.75-7.52)
History of smoking 
No 643 (57.7) 632 (57.5) 11 (73.3) 1 ( 0.239
Yes 463 (41.6) 459 (41.7) 4 (26.7) 0.50 (0.16-1.58)
Unknown 8 (0.7) 8 (0.7) 0 (
ECOG PS
0-1 733 (65.8) 723 (65.8) 10 (66.7) 1 ( 0.978
2-4 372 (33.4) 367 (33.4) 5 (33.3) 0.99 (0.33-2.90)
Unknown 9 (0.8) 9 (0.8) 0 (
Comorbidities
Diabetes
No 941 (84.5) 927 (84.3) 14 (93.3) 1 ( 0.409
Yes 157 (14.1) 156 (14.2) 1 (6.7) 0.42 (0.06-3.25)
Unknown 16 (1.4) 16 (1.5) 0 (
Hypertension
No 742 (66.6) 729 (66.3) 13 (86.7) 1 ( 0.133a)
Yes 355 (31.9) 353 (32.1) 2 (13.3) 0.32 (0.07-1.42)
Unknown 17 (1.5) 17 (1.5) 0 (
History of tuberculosis
No 896 (80.4) 884 (80.4) 12 (80.0) 1 ( 0.866
Yes 201 (18.0) 198 (18.0) 3 (20.0) 1.12 (0.31-3.99)
Unknown 17 (1.5) 17 (1.5) 0 (
Interstitial lung disease
No 1,096 (98.4) 1,082 (98.5) 14 (93.3) 1 ( 0.155a)
Yes 18 (1.6) 17 (1.5) 1 (6.7) 4.55 (0.57-36.56)
Emphysema 
No 907 (81.4) 895 (81.4) 12 (80.0) 1 ( 0.887
Yes 207 (18.6) 204 (18.6) 3 (20.0) 1.10 (0.31-3.92)
Histological type 
Adenocarcinoma 797 (71.5) 787 (71.6) 10 (66.7) 1 ( 0.674
Others 317 (28.5) 312 (28.4) 5 (33.3) 1.26 (0.43-3.72)
Previous treatment
Chest surgery
No 905 (81.2) 894 (81.3) 11 (73.3) 1 ( 0.434
Yes 209 (18.8) 205 (18.7) 4 (26.7) 1.58 (0.50-5.03)
Thoracic radiotherapy 
No 894 (80.3) 881 (80.2) 13 (86.7) 1 ( 0.534
Yes 220 (19.7) 218 (19.8) 2 (13.3) 0.62 (0.14-2.78)
Chemotherapy
No 169 (15.2) 169 (15.2) 0 ( 1 ( 0.995
Yes 945 (84.8) 930 (84.6) 15 (100) 0.00 (
Laboratory results at baseline
Hemoglobin (g/dL) 11.84±1.74 11.85±1.74 11.02±1.37
< 10 147 (13.2) 144 (13.1) 3 (20.0) 1 ( 0.438
" 10 967 (86.8) 955 (86.9) 12 (80.0) 0.60 (0.17-2.16)
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at the time of ILD development was 3.03 g/dL. In two 
patients (13.3%), nosocomial pneumonia occurred during
treatment of ILD.
4. Treatment and outcomes of gefitinib-induced ILD
Treatment and outcomes of gefitinib-induced ILD are sum-
marized in Table 3. Gefitinib was immediately discontinued
in all patients when ILD was clinically suspected. None of
these patients were rechallenged with gefitinib. Two patients
received chemotherapy after ILD improved. One patient 
underwent pemetrexed treatment and the other received 
erlotinib. The patient treated with erlotinib began medication
3 months after development of gefitinib-induced ILD. She 
received erlotinib treatment for 1 month but had to stop the
medication due to newly appeared multifocal patch ground-
glass opacities in both lungs on chest CT. In microbiologic
examinations, sputum pneumocystis jirovecii polymerase
chain reaction was positive, and the patient was treated with
intravenous sulfamethoxazole, trimethoprim, and steroid.
After pneumocystis pneumonia developed, she was trans-
ferred to another hospital near her hometown for hospice
care because of worsened general condition. 
Twelve patients (80.0%) received systemic corticosteroids
for gefitinib-induced ILD. The mean dose was equivalent to
0.87 mg/kg/day methylprednisolone initially and was grad-
ually tapered. Among the 15 patients with gefitinib-induced
ILD, nine patients (60.0%) had a fatal clinical course and six
patients (40.0%) died directly from ILD. The other three 
patients (20.0%) recovered from the potentially fatal ILD con-
dition after stopping the medication or steroid treatment.
However, nosocomial respiratory superinfection developed
in two patients and uncontrolled infection caused their
death. One patient expired from sudden cardiac arrest of 
Table 1. Continued
Variable Total (n=1,114) Gefitinib-induced ILD
No (n=1,099) Yes (n=15) OR (95% CI) p-value
Leukocytes (! 103/µL) 7.71±3.69 7.70±3.67 8.38±4.94
# 10 915 (82.1) 904 (82.3) 11 (73.3) 1 ( 0.375
> 10 199 (17.9) 195 (17.7) 4 (26.7) 1.69 (0.53-5.35)
Creatinine (mg/dL) 0.94±0.35 0.94±0.35 0.78±0.17
# 1.3 1,061 (95.2) 1,046 (95.2) 15 (100) 1 ( 0.998
> 1.3 53 (4.8) 53 (4.8) 0 ( 0.00 (
AST (IU/L) 24.77±15.43 24.80±15.51 22.27±6.46
# 40 1,029 (92.4) 1,014 (92.3) 15 (100) 1 ( 0.997
> 40 85 (7.6) 85 (7.7) 0 ( 0.00 (
ALT (IU/L) 24.71±31.49 24.84±31.67 15.13±9.07
# 40 987 (88.6) 972 (88.4) 15 (100) 1 ( 0.996
> 40 127 (11.4) 127 (11.6) 0 ( 0.00 (
Albumin (g/dL) 3.84±0.52 3.85±0.52 3.51±0.58
> 3.0 1,005 (90.2) 994 (90.4) 11 (73.3) 1 ( 0.037a)
# 3.0 109 (9.8) 105 (9.6) 4 (26.7) 3.44 (1.08-11.00)
Values are presented as mean±standard deviation or number (%) unless otherwise stated. OR, odds ratio; CI, confidence 
interval; ECOS PS, Eastern Cooperative Oncology Group performance status; AST, aspartate transaminase; ALT, alanine
transaminase. a)Data used for multivariate analysis of risk factors for gefitinib-induced ILD.  
Table 2. Multivariate analysis of risk factors for gefitinib-induced interstitial lung disease
Variable Adjusted odds ratio 95% Confidence interval p-value
Sex (female vs. male) 2.77 0.85-9.04 0.092
Hypertension (yes vs. no) 0.29 0.06-1.33 0.111
Interstitial lung disease (yes vs. no) 8.33 0.95-73.37 0.056
Albumin (# 3.0 g/dL vs. > 3.0 g/dL) 3.91 1.20-12.71 0.024
Seung-Hoon Beom, Gefitinib and Pulmonary Toxicity in Korean Lung Cancer Patients
VOLUME 48  NUMBER 1  JANUARY  2016 93
unknown cause when he under observation in a general
ward as gefitinib-induced ILD improving after steroid treat-
ment. The median survival time from onset of ILD was 7.10
weeks. 
We compared the clinical and laboratory variables of the
fatal and non-fatal cases of ILD and found that patients in
the fatal group developed ILD after a shorter median length
of gefitinib administration and had lower mean SpO2 and
lower albumin level at the time of ILD development than did
the non-fatal group (Table 3). However, the fatal and non-
fatal groups did not differ significantly in underlying comor-
bidities, pulmonary disease, types of previous cancer
treatment, time interval from onset of ILD to cessation of
gefitinib or administration of corticosteroids, and methyl-
prednisolone dosage.
Discussion
Gefitinib is recognized as an acceptably safe oral agent,
given that the most common toxicities associated with its
use are mild and self-limiting, such as skin toxicities and 
diarrhea [1]. However, the development of ILD during gefi-
tinib treatment is a drug-related toxicity that sometimes has
serious consequences. In 2003, an Food and Drug Adminis-
tration (FDA) analysis of 50,000 patients who received gefi-
tinib reported a 1% worldwide incidence of ILD [1].
Notably, the incidence of ILD in Japanese populations was
reported to range between 2.4% and 5.4% in clinical trials
[9,13-18]. In other Asian studies, the incidence of ILD also
exceeds the global incidence; in Taiwanese patients, it was
reported at 2.3% [19]. However, the incidence of ILD in our
study was 1.3%, similar to values reported worldwide. This
is much lower than reported in other Asian populations, 
including studies of Japanese and Taiwanese patients (Table 4). 
Risk factors for ILD have been identified in several Japan-
ese studies (Table 4), but the findings from the reported stud-
ies are inconsistent. In the present study, we attempted to
identify risk factors for ILD in gefitinib-treated NSCLC 
patients by collecting all possible risk factors, including 
laboratory results and clinical factors that were evaluated in
previous studies. Unlike the previous results, a lower serum
albumin level at the time of gefitinib treatment initiation was
the only risk factor for developing gefitinib-induced ILD. A
smaller Japanese study evaluated the association between
ILD and several laboratory values including albumin level,
but did not find a significant association [16].
The mechanism by which gefitinib may cause ILD is 
unclear. However, decreased EGFR phosphorylation result-
ing in a decrease in regenerative epithelial proliferation could
augment pulmonary fibrosis [20]. We found that a lower
serum albumin level might be an important surrogate
marker for predicting gefitinib-induced ILD. Notably, the 
albumin level at the time of ILD development decreased
compared to that before gefitinib administration (from a
mean of 3.51 to 3.03 g/dL). A similar phenomenon occurs
with methotrexate therapy. Methotrexate is a commonly 
prescribed antineoplastic agent and an immune modulating
compound. Its pulmonary toxicities are well described. 
Hypoalbuminemia is a predisposing factor for methotrexate-
induced pulmonary toxicity (either before or during therapy)
[21]. It has been hypothesized that a lower degree of protein
binding of methotrexate and higher levels of free methotrex-
ate resulting from hypoalbuminemia could enhance drug-
induced pulmonary toxicity in methotrexate-treated patients
[21]. Gefitinib is also primarily bound to plasma proteins 
including human serum albumin (90%) and alpha-1 acid 
glycoprotein (78%) [22]. Similarly, methotrexate is bound to
plasma protein (~50%). Ter Heine et al. [23] reported a case
of fatal ILD associated with another EGFR tyrosine kinase 
inhibitor erlotinib, with high erlotinib and metabolite plasma
levels, and suggested that high drug and metabolite levels
result in severe adverse pulmonary reactions. With these
drugs, a lower albumin level might lead to higher levels of
free gefitinib and enhance pulmonary toxicity. In a study of
another target agent, monoclonal antibodies, low albumin
level was identified as a risk factor for developing adverse
pulmonary reactions in cancer patients [12]. However, the
cause for gefitinib-associated ILD is multifactorial and it is
difficult to demonstrate causation between hypoalbumine-
mia and the development of gefitinib-induced ILD from the
results in our study. In addition, hypoalbuminemia in itself
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Fig. 2.  Cumulative incidence of gefitinib-induced inter-
stitial lung disease.
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Table 3. Clinical features and outcomes of gefitinib-induced interstitial lung disease (ILD)
Variable Total (n=15) Non-fatal (n=6) Fatal (n=9) p-value
Clinical findings
Mean age (yr) 60.69±12.01 66.93±10.60 56.53±11.55 0.101 
Sex (male:female) 4 (26.7):11 (73.3) 0 (0):6 (100) 4 (44.4):5 (55.6) 0.103 
Current or ex-smoker 4 (26.7) 0 ( 4 (44.4) 0.103 
ECOG PS (" 2) 5 (33.3) 3 (50.0) 2 (22.2) 0.329 
Emphysematous lung 3 (20.0) 0 ( 3 (33.3) 0.229 
Previous treatment
Chest surgery 4 (26.7) 2 (33.3) 2 (22.2) > 0.999  
Thoracic radiotherapy 2 (13.3) 1 (16.7) 1 (11.1) > 0.999 
Chemotherapy 15 (100) 6 (100) 9 (100) > 0.999 
Combined lung cancer progression 3 (20.0) 1 (16.7) 2 (22.2) > 0.999 
Responder to gefitinib 1 (6.7) 1 (16.7) 0 ( 0.400 
Onset of symptoms after gefitinib 29.0 (3-1,953) 54.0 (14-1,953) 10.0 (3-56) 0.024 
therapy, median (range, day)
# 8 wk 12 (80.0) 3 (50.0) 9 (100) 0.044
> 8 wk 3 (20.0) 3 (50.0) 0 (
Symptoms
Dyspnea 15 (100) 6 (100) 9 (100) > 0.999
Cough 9 (60.0) 4 (66.7) 5 (55.6) > 0.999 
Chest discomfort 2 (13.3) 0 ( 2 (22.2) 0.486 
Fever " 38.0°C 2 (13.3) 0 ( 2 (22.2) 0.486 
SpO2 (%) (n=13) 80.47±20.32 96.75±2.06 73.23±20.65 0.009 
Laboratory findings at the time of ILD onset  
Leukocytes (!103/µL) 13.90±8.47 9.08±2.35 17.12±9.68 0.070 
Eosinophil percentage 2.52±2.60 3.05±2.53 2.17±2.74 0.539 
Hemoglobin (g/dL) 10.86±1.97 11.17±2.61 10.66±1.56 0.641 
CRP (mg/dL) (n=13) 12.01±8.78 7.72±10.31 13.92±7.91 0.257 
Albumin (g/dL) 3.03±0.56 3.55±0.45 2.69±0.31 0.001 
Treatment
Cessation of gefitinib treatment 15 (100) 6 (100) 9 (100) > 0.999 
Interval from onset of symptoms to 8.21±8.12 10.80±7.66 6.78±8.44 0.396
cessation of gefitinib (day) 
Administration of corticosteroids 12 (80.0) 4 (66.7) 8 (88.9) 0.525 
Methylprednisolone dose 0.87±0.61 0.52±0.42 1.06±0.63 0.110 
(mg/kg/day) at first
Duration of corticosteroids treatment (day) 34.08±34.24 61.50±45.86 20.38±17.22 0.170 
Interval from symptom onset to start 5.64±4.38 8.20±6.02 4.22±2.59 0.087 
of corticosteroids (day)
Coadministration of antibiotics 12 (80.0) 4 (66.7) 8 (88.9) 0.220 
Clinical course
ILD-related death 6 (40.0) 0 ( 6 (66.7) 0.028 
Median survival time after ILD onset (wk) 7.10±2.93 16.00±2.12 4.10±3.58 < 0.001
Subsequent chemotherapy after ILD 0.177 
Cytotoxic chemotherapy 1 (6.7) 1 (16.7) 0 (
Erlotinib 1 (6.7) 1 (16.7) 0 (
Values are presented as mean±standard deviation or number (%) unless otherwise stated. ECOG PS, Eastern Cooperative 
Oncology Group performance status.
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is a marker for illness severity and malnutrition, and many
confounding clinical factors can influence the development
of hypoalbuminemia. 
Another possible predisposing factor for gefitinib-induced
ILD is ethnic differences in susceptibility to ILD. Notably, the
incidence of gefitinib-induced ILD in Japanese patients was
higher than the incidence found in our study; the incidence
in our study was similar to values reported in worldwide
populations. Forsythe and Faulkner [24] suggest that the rea-
son for the observed difference in susceptibility to ILD is 
related to population or environmental differences or differ-
ences in diagnostic or clinical practice. A higher risk of ILD
has been noted in Japan than elsewhere with other medica-
tions [25]. In fact, the frequency of coincidence with intersti-
tial pneumonitis before gefitinib treatment was much higher
(5.0%-13.6%) [13-17] than that observed in our Korean pop-
ulation (1.6%). Of note, comorbid interstitial pneumonitis
was found to be a major risk factor for gefitinib-induced ILD
in many Japanese studies (Table 4). 
Gefitinib-induced ILD usually occurs during the first 3
months of treatment; the range to onset is 24 to 42 days [1].
In our study, the median time to development of ILD was 29
days, and 80.0% of ILD cases presented within the first 8
weeks of starting gefitinib treatment (Fig. 2). The main man-
ifestations of gefitinib-induced ILD were dyspnea (100.0%)
and cough (60.0%), sequentially, while only two patients
(13.3%) presented with fever, a commonly recognized sign
of infectious pneumonia. 
The prognosis for gefitinib-induced ILD was consistent
with other studies (Table 4). In the present study, among 
patients diagnosed with ILD, six patients had an ILD related
death (mortality, 40.0%). Treatment of gefitinib-induced ILD
is largely supportive, including supplemental oxygen, 
empirical antibiotics and mechanical ventilation. Immediate
discontinuation of the drug is strongly recommended and
systemic corticosteroids are usually prescribed, although 
no controlled trials have been conducted to evaluate their 
efficacy [5].
We investigated the association between clinical factors at
the time of onset and fatality from gefitinib-induced ILD. In
this study, the treatment for gefitinib-induced ILD was not
significantly different between the fatal and non-fatal groups.
When ILD was suspected clinically, gefitinib was discontin-
ued immediately in all patients. The time interval from onset
of symptoms to cessation of gefitinib was similar between
groups. Among the 15 patients who developed ILD, 12 
Table 4. Reported incidence, mortality and risk factors of gefitinib-induced interstitial lung disease (ILD) in Japanese [9,13-
18] and Taiwanese [19] studies
Year Study group No. of No. cases of No. ILD death Risk factorpatients ILD (%) (mortality, %)
2004 National Cancer Center, 112 6 (5.4) 4 (66.7) Preexisting pulmonary fibrosis
Japan [14]
2005 Okayama Lung Cancer Study 330 15 (4.5) 8 (53.3) Preexisting pulmonary fibrosis, poor PS, 
Group [15] prior thoracic irradiation
2006 West Japan Thoracic Oncology 1,976 70 (3.5) 31 (44.3) Preexisting pulmonary fibrosis, male, 
Group [13] smoking
2008 AstraZeneca [9] 1,482 59 (4.0) -  (31.6) Preexisting chronic ILD, poor PS, smoker, 
older age (> 55 years), recent NSCLC 
diagnosis, reduced normal lung on 
computed tomography scan, concurrent 
cardiac disease
2009 Japan-Multinational Trial 526 17 (3.2) 7 (41.2) No risk factors found 
Organization [16]
2010 Okayama Lung Cancer Study 330 8 (2.4) 5 (62.5) Preexisting pulmonary fibrosis, poor PS
Group [17]
2013 NEJ 002 and WJTOG 3405 201 10 (5.0) 2 (20.0) Smoking 
trials [18] (EGFRmutation 
positive)
2013 Chang et al. [19] 1,080 25 (2.3) 10 (40.0) Not evaluated 
2013 This study 1,114 15 (1.3) 6 (40.0) Lower albumin level 
PS, performance status; NSCLC, non-small cell lung cancer.
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